At a glance
ClinicalIndex Comparison RecordN/ACompleted· 466,991 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants
In Brief
An observational study for Non-Valvular Atrial Fibrillation. Completed, enrolled 466,991 participants across 1 site.
Detailed Summary
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban or dabigatran or rivaroxaban treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Valvular Atrial Fibrillation
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJun 2016
First PostedMar 2017
Primary CompletionFeb 2023
Study CompletionMar 2023
TodayJul 2026
First PostedMar 22, 2017
Enrollment StartJun 1, 2016
Primary CompletionFeb 26, 2023
Study CompletionMar 8, 2023
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.3 years ago